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includes cardiogenic shock in 18 patients (38%) and postcardiotomy cardiogenic
shock in 29 patients (62%). Thirty-eight patients of the 47 total patients (80%)
were supported withImpella 5.0/LD and with Impella 2.5 for the remaining 9
(19%) patients. . The 30-day survival rate was 75% (35/47) and of those 97%
(34/35) recovered their native heart function and 1 (3%) was bridged to long term
ventricular assist device Complications occurred in 14 (30%) patients and
consisted of device malfunction (11%), high purge pressures (6%), catheter
fracture (2%), and groin hematoma (2%).
Conclusions: The outcomes from our study were very favorable; myocardial
recovery was accomplished in the majority of the patients with acceptable
complication rate in these critically ill patients. These benefits encourage the use
of a less invasive circulatory support with Impella in the setting of cardiogenic
shock.
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Background: CD133	 progenitor cells are considered an inmature population of
haematopoietic stem cells with the capacity to differentiate into endothelial cells.The aim
of this study was to assess the safety and the feasibility of transendocardial injection of
selected CD133	 cells in patients (pts) with refractory angina without any option of
revascularization.
Methods: The PROGENITOR trial is a randomized, blinded, multicenter con-
trolled trial. Pts with class II-IV angina and with ischemic/viable zone demon-
strated with SPECT without any option of revascularization were included. All Pts
were treated for 4-days with G-CSF and undergo apheresis to isolate the cells
from the peripheral blood. CD133	 cells were selected with CliniMacs system
(Miltenyi Biotec). The cells were injected transendocardially, guided by electro-
mechanical mapping with the NOGA system.
Results: 28 pts were included. The mean age 649, 85% were male, 53% were
diabetics and 85% had previous surgery. The dose of injected cells was 30
millions with 85% of CD133	 purity. One pt allocated to the placebo group
suffered ventricular fibrillation 24-hours after the baseline procedure and an ICD
was implanted. This pt died at 3.5 months of follow-up due to a cardiovascular
cause. One pt from the treatment group presented VT during the injection that was
successfully cardioverted. One pt from the treatment group had a cardiac
tamponade during mapping that was revolved, but the pt died due to cardiogenic
shock. No more events were recorded.
Conclusions: this is the first-in-man trial with transendocardial injection of
selected CD133	 cells in no-option pts. To date, these results suggest the safety
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Background: Single center studies, using serial cerebral diffusion-weighted magnetic
resonance imaging in patients having cardiac catheterization have suggested that cerebral
microembolism might be responsible for silent cerebral infarct as high as 15 to 22%. We
evaluated in a multicenter trial the incidence of silent cerebral infarcts after cardiac
catheterization and whether or not the choice of the arterial access site might impact this
phenomenon.
Methods: Patients were randomized to have cardiac catheterization either by Radial
(n83) or Femoral (n77) arterial approaches by experimented operators. The main
outcome measure was the occurrence of new cerebral infarct on serial diffusion-weighted
magnetic resonance imaging.
Results: Patient and catheterization characteristics, including duration of catheterization,
were similar in both groups. The risk of silent cerebral infarct did not differ significantly
between the Femoral and Radial groups (incidence of 11.7% versus 17.5%; odds ratio
[OR], 0.85; 95% confidence interval [CI], 0.62-1.16; p 0.31). At multivariable analysis,
the independent predictors of silent cerebral infarct were the patient’s higher height and
lower transvalvular gradient.
Conclusions: The high rate of silent cerebral infarct after cardiac catheterization of
patients with aortic stenosis was confirmed, but its occurrence was not affected by the
selection of Radial and Femoral access.
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Background: Obtaining safe and effective closure of the femoral access site following
percutaneous coronary interventions (PCI) can sometimes be challenging, especially in
patients on anti-coagulation or anti-platelet therapy. Vascular closure devices (VSC) have
been shown to shorten hemostasis time, reduce the discomfort of manual or mechanical
compression, and allow for earlier ambulation after percutaneous invasive procedures
without increasing vascular complications compared with conventional compression
techniques. The 6 French EXOSEAL, a new vascular closure device, is composed of a
bioabsorbable plug and a Plug Delivery System which positions and releases the
bioabsorbable plug to the extravascular surface of the femoral artery. The objective of this
prospective randomized study was to compare the efficacy and safety of the 6 French
EXOSEAL (Cordis) versus the PERCLOSE PROGLIDE in patients undergoing PCI and
endovascular peripheral procedures via a retrograde femoral artery access.
Methods: From January 2011 to November 2011, 100 Patients were enrolled in this
single-center trial. Immediately after the coronary or peripheral procedure, they were
randomly assigned to PROGLIDE (n:50) versus EXOSEAL (n:50). The end points were
the immediate total hemostasis and the incidence of vascular complication.
Results: There were no significant differences in baseline characteristics between the 2
treatment groups. Immediate total hemostasis was achieved with the EXOSEAL device in
46 patients (92%) versus 44 patients with the PROGLIDE device (88%) (p: 0,74). 4
patients needed additional action (manual or mechanical compression) in the EXOSEAL
group versus 6 in the PROGLIDE group (8% versus 12%, p: 0,74). 2 patients experienced
a minor complication (hematoma  5cm) in the EXOSEAL group versus 3 in the
PROGLIDE group (4% vs 6%, p:0,54). . No other vascular complication occurred and no
transfusion were necessary.
Conclusions: After percutaneous invasive procedures, the difference between the
EXOSEAL and the PROGLIDE devices concerning the incidence of immediate
total hemostasis, and vascular complication did not reach statistical significance.
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